The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
about
Hypoglycemic agents and potential anti-inflammatory activityNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationDPP4 in DiabetesDoes tight control of systemic factors help in the management of diabetic retinopathy?Improvements in the Management of Diabetic NephropathyAlogliptin benzoate for management of type 2 diabetesTissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.The regulatory role of DPP4 in atherosclerotic disease.Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.Linagliptin alleviates fatty liver disease in diabetic db/db miceVildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.A khorasan wheat-based replacement diet improves risk profile of patients with type 2 diabetes mellitus (T2DM): a randomized crossover trialA review of gliptins for 2014.Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Innovative biomarkers for predicting type 2 diabetes mellitus: relevance to dietary management of frailty in older adults.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY).Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!The "Evidence" Is In! It Does Get Better!Effects of Incretin-Based Therapies on Diabetic Microvascular Complications.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM).How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors.The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes.Endogenous dipeptidyl peptidase IV modulates skeletal muscle arteriolar diameter in rats.Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis.The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.[Diabetic kidney disease - Update 2016].
P2860
Q26750414-0A570547-9565-4C85-8500-8EA45A7D72B8Q26777994-CE8D4653-7D9D-4448-99AD-A77334F5CF64Q26778329-1827DAE1-06BB-47D4-98DC-BC256D1F1531Q26797335-9EC33378-7FE5-4CE8-824C-20B723057438Q28074223-CCA2C9CE-892E-455D-BC91-470A680B5027Q28080717-0FF68FFF-1C37-442A-A763-F44AAC985470Q28083933-FFB3BB7B-E691-43CB-B123-1680C03BCE7DQ31036099-77B53B2E-425C-42A3-8032-973D3918F9E5Q33805518-D997CF40-66B8-4C3B-9ED0-D5A3AC545156Q35330816-70B599DB-FC05-411E-A7B7-39CDC5FB35A9Q36758314-6900A0B4-26E2-491D-9242-32FF84CAD797Q37411528-BBCDE3E7-EBCD-48D2-80FB-3ED76270F540Q37663425-6FC46C49-8B47-4431-903C-877F62CD3967Q37694302-8BB5FF22-3E81-4714-ABBD-AA1001FDA5ADQ38266290-734A17F3-0183-4669-8A7C-5B551F5876DBQ38315999-922D39CA-212F-4D26-8356-AF03E659E285Q38527885-A5C910DA-7B05-41B7-8211-DF8CFF37054BQ38742179-826C0C3E-28F9-4FD3-8EB8-3844907CA457Q38820260-B0CAA64F-2257-4CE7-A883-684BD1CD3E60Q39259711-3AC524F0-F2D4-4108-B088-7EBD202A9B22Q42360594-B378AABA-2253-4D74-A488-9AA53C4333E2Q42360610-2126E30E-6657-4613-8BBE-060FA337AEDBQ42366423-A0267BC3-49D9-49C6-85FB-5FD0BDD92996Q42876331-7B6EBCC9-1B43-433F-BC1B-6FBD4383DD9CQ47144226-4AA80D84-ECB2-41D3-BC7C-320E5AAC8DC7Q48113639-27D570ED-E7C3-499E-945F-9C0832880DEAQ48713671-7A4EFA9A-E716-4330-B737-737204D349E4Q49583254-3EF2E262-ABEC-44DA-A9BD-BFC55F16248BQ51307150-BD1B0C3B-54B2-4583-A00A-D7B7F3CADCB8Q52718518-A7F65CFA-4FB9-4CA6-986D-24695A3D0B30Q53620509-5E4214E2-87F8-48EE-B796-BBFB345D877A
P2860
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
@en
type
label
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
@en
prefLabel
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
@en
P356
P1433
P1476
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications
@en
P2093
Angelo Avogaro
P304
P356
10.2337/DC14-0865
P407
P577
2014-10-01T00:00:00Z